S. Ravichandran

Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial

Antônio Roberto Chacra, G. H. Tan, Anne Marie Apanovitch et al. · International Journal of Clinical Practice · 2009 · 237 citations · Full text

Long-term treatment of Cushing’s disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial

Stephan Petersenn, L R Salgado, Jochen Schopohl et al. · Endocrine · 2017 · 59 citations · Full text

Long‐term 4‐year safety of saxagliptin in drug‐naive and metformin‐treated patients with Type 2 diabetes

Julio Rosenstock, Jorge Luiz Gross, Carlos A. Aguilar‐Salinas et al. · Diabetic Medicine · 2013 · 30 citations

Long-acting pasireotide improves clinical signs and quality of life in Cushing’s disease: results from a phase III study

André Lacroix, Marcello D. Bronstein, Jochen Schopohl et al. · Journal of Endocrinological Investigation · 2020 · 27 citations

Long-acting Pasireotide, Clinical Signs, Pathology +5

IOT-based cyber security identification model through machine learning technique

Bechoo Lal, S. Ravichandran, R. Kavin et al. · Measurement Sensors · 2023 · 19 citations · Full text